Siroos Mirzaei: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
m PMID, doi using AWB
Line 28: Line 28:


==Biography==
==Biography==
Mirzaei spent his childhood and adolescence in Mashhad, Iran. When he was 18 years old, he moved to Austria to study [[medicine]] at the [[University of Vienna]].<ref name=a>[http://www.vienna-omi.at/en/uploads/pdf/mentors/WIL_Mirzaei.pdf CV Mirzaei Siroos]</ref> He graduated in 1987 and after some experimental jobs i.e. at the Department of Experimental Anesthesiology of the Vienna General Hospital he moved in 1989 to [[Luxemburg]] to continue his postdoctoral education at the Department of Cardiology and the Department of Infectious Diseases of the [[Centre Hospitalier de Luxembourg]]. In 1994 he completed his specialist training in Family Medicine at the Kaiserin Elisabeth Hospital in Vienna and received the Board Certification in General Medicine. In 1994, he changed to Wilhelminen Hospital in Vienna to complete his specialist medical training in Nuclear Medicine which he was certified for in 1998. In the same year, Mirzaei went to [[Heidelberg| Heidelberg, Germany]] for a research sabbatical at the Department of [[Endocrinology]] of the [[Ruprecht-Karls-University]] and afterwards he started to work as Staff Physician at the Wilhelminen Hospital Vienna. In 2004, Mirzaei was appointed professor for Nuclear Medicine at the University of Vienna. Since 2007, he has been Head of the Department of Nuclear Medicine at the Wilhelminen Hospital Vienna.<ref name=b>[http://www.nuklearmedizin-wsp.at Department of Nuclear Medicine, Wilhelminen Vienna]</ref>
Mirzaei spent his childhood and adolescence in Mashhad, Iran. When he was 18 years old, he moved to Austria to study [[medicine]] at the [[University of Vienna]].<ref name=a>[http://www.vienna-omi.at/en/uploads/pdf/mentors/WIL_Mirzaei.pdf CV Mirzaei Siroos]</ref> He graduated in 1987 and after some experimental jobs i.e. at the Department of Experimental Anesthesiology of the Vienna General Hospital he moved in 1989 to [[Luxemburg]] to continue his postdoctoral education at the Department of Cardiology and the Department of Infectious Diseases of the [[Centre Hospitalier de Luxembourg]]. In 1994 he completed his specialist training in Family Medicine at the Kaiserin Elisabeth Hospital in Vienna and received the Board Certification in General Medicine. In 1994, he changed to Wilhelminen Hospital in Vienna to complete his specialist medical training in Nuclear Medicine which he was certified for in 1998. In the same year, Mirzaei went to [[Heidelberg| Heidelberg, Germany]] for a research sabbatical at the Department of [[Endocrinology]] of the [[Ruprecht-Karls-University]] and afterwards he started to work as Staff Physician at the Wilhelminen Hospital Vienna. In 2004, Mirzaei was appointed professor for Nuclear Medicine at the University of Vienna. Since 2007, he has been Head of the Department of Nuclear Medicine at the Wilhelminen Hospital Vienna.<ref name="b"/>


==Scientific contribution==
==Scientific contribution==
Mirzaei has been contributing to the following fields of research:
Mirzaei has been contributing to the following fields of research:
* Medical evidence on traces of torture with nuclear medicine methods<ref>Zandieh S, Bernt R, Knoll P, Wenzel T, Hittmair K, Haller J, Hergan K, Mirzaei S. Analysis of the Metabolic and Structural Brain Changes in Patients With Torture-Related Post-Traumatic Stress Disorder (TR-PTSD) Using 18F-FDG PET and MRI. Medicine (Baltimore). 2016 Apr;95(15):e3387. doi:10.1097/MD.0000000000003387. PubMed PMID: 27082610; PubMed Central PMCID:PMC4839854.</ref><ref>Wenzel T, Frewer A, Mirzaei S. The DSM 5 and the Istanbul Protocol: Diagnosis of psychological sequels of torture. Torture. 2015;25(1):51-61. Review. PubMed PMID:26021347.</ref><ref>Mirzaei S, Sonneck-Koenne C, Bruecke T, Aryana K, Knoll P, Zakavi R. Supplementary value of functional imaging in forensic medicine. Torture. 2012;22 Suppl 1:14-20. PubMed PMID:22948398.</ref><ref>Mirzaei S, Knoll P, Köhn H. [Medical aspects of objectifying torture sequels]. Wien Klin Wochenschr. 2004 Aug 31;116(15-16):568-74. German. PubMed PMID: 15471186.</ref><ref>Mirzaei S, Knoll P, Keck A, Preitler B, Gutierrez E, Umek H, Köhn H, Pecherstorfer M. Regional cerebral blood flow in patients suffering from post-traumatic stress disorder. Neuropsychobiology. 2001;43(4):260-4. PubMed PMID: 11340366.</ref><ref>Wenzel T, Griengl H, Stompe T, Mirzaei S, Kieffer W. Psychological disorders in survivors of torture: exhaustion, impairment and depression. Psychopathology. 2000 Nov-Dec;33(6):292-6. PubMed PMID: 11060511.</ref><ref>Mirzaei S, Knoll P, Lipp RW, Wenzel T, Koriska K, Köhn H. Bone scintigraphy in screening of torture survivors. Lancet. 1998 Sep 19;352(9132):949-51. PubMed PMID: 9752817.</ref>
* Medical evidence on traces of torture with nuclear medicine methods<ref>Zandieh S, Bernt R, Knoll P, Wenzel T, Hittmair K, Haller J, Hergan K, Mirzaei S. Analysis of the Metabolic and Structural Brain Changes in Patients With Torture-Related Post-Traumatic Stress Disorder (TR-PTSD) Using 18F-FDG PET and MRI. Medicine (Baltimore). 2016 Apr;95(15):e3387. {{doi|10.1097/MD.0000000000003387}}. PubMed PMID 27082610; PubMed Central PMCID:PMC4839854.</ref><ref>Wenzel T, Frewer A, Mirzaei S. The DSM 5 and the Istanbul Protocol: Diagnosis of psychological sequels of torture. Torture. 2015;25(1):51-61. Review. PubMed PMID 26021347.</ref><ref>Mirzaei S, Sonneck-Koenne C, Bruecke T, Aryana K, Knoll P, Zakavi R. Supplementary value of functional imaging in forensic medicine. Torture. 2012;22 Suppl 1:14-20. PubMed PMID 22948398.</ref><ref>Mirzaei S, Knoll P, Köhn H. [Medical aspects of objectifying torture sequels]. Wien Klin Wochenschr. 2004 Aug 31;116(15-16):568-74. German. PubMed PMID 15471186.</ref><ref>Mirzaei S, Knoll P, Keck A, Preitler B, Gutierrez E, Umek H, Köhn H, Pecherstorfer M. Regional cerebral blood flow in patients suffering from post-traumatic stress disorder. Neuropsychobiology. 2001;43(4):260-4. PubMed PMID 11340366.</ref><ref>Wenzel T, Griengl H, Stompe T, Mirzaei S, Kieffer W. Psychological disorders in survivors of torture: exhaustion, impairment and depression. Psychopathology. 2000 Nov-Dec;33(6):292-6. PubMed PMID 11060511.</ref><ref>Mirzaei S, Knoll P, Lipp RW, Wenzel T, Koriska K, Köhn H. Bone scintigraphy in screening of torture survivors. Lancet. 1998 Sep 19;352(9132):949-51. PubMed PMID 9752817.</ref>
* Application of [[PET-CT]] in [[oncology]]<ref>Capasso E, Durzu S, Piras S, Zandieh S, Knoll P, Haug A, Hacker M, Meleddu C, Mirzaei S. Role of (64)CuCl 2 PET/CT in staging of prostate cancer. Ann Nucl Med. 2015 Jul;29(6):482-8. doi: 10.1007/s12149-015-0968-4. Epub 2015 Apr 2. PubMed PMID: 25833290.</ref><ref>Zandieh S, Pokieser W, Knoll P, Sonneck-Koenne C, Kudlacek M, Mirzaei S. Oncocytic adenomas of thyroid-mimicking benign or metastatic disease on 18F-FDG-PET scan. Acta Radiol. 2015 Jun;56(6):709-13. doi: 10.1177/0284185114537928. Epub 2014 Jun 19. PubMed PMID: 24948789.</ref><ref>Ahmadzadehfar H, Rodrigues M, Zakavi R, Knoll P, Mirzaei S. Prognostic significance of the standardized uptake value of pre-therapeutic (18)F-FDG PET in patients with malignant lymphoma. Med Oncol. 2011 Dec;28(4):1570-6. doi:10.1007/s12032-010-9584-2. Epub 2010 Jun 4. PubMed PMID:20524086.</ref><ref>Prosch H, Mirzaei S, Oschatz E, Strasser G, Huber M, Mostbeck G. Case report: Gluteal injection site granulomas: false positive finding on FDG-PET in patients with non-small cell lung cancer. Br J Radiol. 2005 Aug;78(932):758-61. PubMed PMID: 16046432.</ref><ref>Fink AM, Holle-Robatsch S, Herzog N, Mirzaei S, Rappersberger K, Lilgenau N, Jurecka W, Steiner A. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res. 2004 Apr;14(2):141-5. PubMed PMID: 15057045.</ref><ref>Mirzaei S, Guerchaft M, Bonnier C, Knoll P, Doat M, Braeutigam P. Use of segmented CT transmission map to avoid metal artifacts in PET images by a PET-CT device. BMC Nucl Med. 2005 Jun 14;5(1):3. PubMed PMID: 15953395; PubMed Central PMCID: PMC1164418.</ref><ref>Mirzaei S, Schratter-Sehn AU, Knoll P, Gerber E, Kumpan W, Schiessel R, Raderer M, Köhn H. [Determination of therapy management in rectal carcinoma by staging with 18-FDG-PET]. Chirurg. 2001 Sep;72(9):1058-61. German. PubMed PMID:11594277.</ref><ref>Mirzaei S, Knoll P, Kohn H. Diagnosis of recurrent astrocytoma with fludeoxyglucose F18 PET scanning. N Engl J Med. 2001 Jun 28;344(26):2030-1. PubMed PMID: 11430342.</ref> and [[dementia]] diagnostics.<ref>Dimou E, Booij J, Rodrigues M, Prosch H, Attems J, Knoll P, Zajicek B, Dudczak R, Mostbeck G, Kuntner C, Langer O, Bruecke T, Mirzaei S. Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment. Curr Alzheimer Res. 2009 Jun;6(3):312-9. Review. PubMed PMID: 19519314.</ref><ref>Mirzaei S, Gelpi E, Booij J, Rodrigues M, Neumann I, Zaknun J, Koehn H, Knoll P. New approaches in nuclear medicine for early diagnosis of Alzheimer's disease. Curr Alzheimer Res. 2004 Aug;1(3):219-29. Review. PubMed PMID: 15975069.</ref><ref>Mirzaei S, Rodrigues M, Koehn H, Knoll P, Bruecke T. Metabolic impairment of brain metabolism in patients with Lewy body dementia. Eur J Neurol. 2003 Sep;10(5):573-5. PubMed PMID: 12940841.</ref><ref>Mirzaei S, Knoll P, Koehn H, Bruecke T. Assessment of diffuse Lewy body disease by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET). BMC Nucl Med. 2003 Feb 20;3(1):1. PubMed PMID: 12625839; PubMed Central PMCID: PMC151666.</ref> Mirzaei and his team are the first center which is applying Cu-64 PSMA in prostate cancer.<ref>B Grubmüller, R P Baum, E Capasso, A Singh, Y Ahmadi, P Knoll, A Floth, S Righi, S Zandieh, C Meleddu, S F Shariat, H C Klingler, S Mirzaei (2016) 64Cu-PSMA-617 PET/CT imaging of prostate adenocarcinoma: First in-human studies Cancer Biotherapy and Radiopharmaceuticals.</ref>
* Application of [[PET-CT]] in [[oncology]]<ref>Capasso E, Durzu S, Piras S, Zandieh S, Knoll P, Haug A, Hacker M, Meleddu C, Mirzaei S. Role of (64)CuCl 2 PET/CT in staging of prostate cancer. Ann Nucl Med. 2015 Jul;29(6):482-8. {{doi|10.1007/s12149-015-0968-4}}. Epub 2015 Apr 2. PubMed PMID 25833290.</ref><ref>Zandieh S, Pokieser W, Knoll P, Sonneck-Koenne C, Kudlacek M, Mirzaei S. Oncocytic adenomas of thyroid-mimicking benign or metastatic disease on 18F-FDG-PET scan. Acta Radiol. 2015 Jun;56(6):709-13. {{doi|10.1177/0284185114537928}}. Epub 2014 Jun 19. PubMed PMID 24948789.</ref><ref>Ahmadzadehfar H, Rodrigues M, Zakavi R, Knoll P, Mirzaei S. Prognostic significance of the standardized uptake value of pre-therapeutic (18)F-FDG PET in patients with malignant lymphoma. Med Oncol. 2011 Dec;28(4):1570-6. {{doi|10.1007/s12032-010-9584-2}}. Epub 2010 Jun 4. PubMed PMID 20524086.</ref><ref>Prosch H, Mirzaei S, Oschatz E, Strasser G, Huber M, Mostbeck G. Case report: Gluteal injection site granulomas: false positive finding on FDG-PET in patients with non-small cell lung cancer. Br J Radiol. 2005 Aug;78(932):758-61. PubMed PMID 16046432.</ref><ref>Fink AM, Holle-Robatsch S, Herzog N, Mirzaei S, Rappersberger K, Lilgenau N, Jurecka W, Steiner A. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res. 2004 Apr;14(2):141-5. PubMed PMID 15057045.</ref><ref>Mirzaei S, Guerchaft M, Bonnier C, Knoll P, Doat M, Braeutigam P. Use of segmented CT transmission map to avoid metal artifacts in PET images by a PET-CT device. BMC Nucl Med. 2005 Jun 14;5(1):3. PubMed PMID 15953395; PubMed Central PMCID: PMC1164418.</ref><ref>Mirzaei S, Schratter-Sehn AU, Knoll P, Gerber E, Kumpan W, Schiessel R, Raderer M, Köhn H. [Determination of therapy management in rectal carcinoma by staging with 18-FDG-PET]. Chirurg. 2001 Sep;72(9):1058-61. German. PubMed PMID 11594277.</ref><ref>Mirzaei S, Knoll P, Kohn H. Diagnosis of recurrent astrocytoma with fludeoxyglucose F18 PET scanning. N Engl J Med. 2001 Jun 28;344(26):2030-1. PubMed PMID 11430342.</ref> and [[dementia]] diagnostics.<ref>Dimou E, Booij J, Rodrigues M, Prosch H, Attems J, Knoll P, Zajicek B, Dudczak R, Mostbeck G, Kuntner C, Langer O, Bruecke T, Mirzaei S. Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment. Curr Alzheimer Res. 2009 Jun;6(3):312-9. Review. PubMed PMID 19519314.</ref><ref>Mirzaei S, Gelpi E, Booij J, Rodrigues M, Neumann I, Zaknun J, Koehn H, Knoll P. New approaches in nuclear medicine for early diagnosis of Alzheimer's disease. Curr Alzheimer Res. 2004 Aug;1(3):219-29. Review. PubMed PMID 15975069.</ref><ref>Mirzaei S, Rodrigues M, Koehn H, Knoll P, Bruecke T. Metabolic impairment of brain metabolism in patients with Lewy body dementia. Eur J Neurol. 2003 Sep;10(5):573-5. PubMed PMID 12940841.</ref><ref>Mirzaei S, Knoll P, Koehn H, Bruecke T. Assessment of diffuse Lewy body disease by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET). BMC Nucl Med. 2003 Feb 20;3(1):1. PubMed PMID 12625839; PubMed Central PMCID: PMC151666.</ref> Mirzaei and his team are the first center which is applying Cu-64 PSMA in prostate cancer.<ref>B Grubmüller, R P Baum, E Capasso, A Singh, Y Ahmadi, P Knoll, A Floth, S Righi, S Zandieh, C Meleddu, S F Shariat, H C Klingler, S Mirzaei (2016) 64Cu-PSMA-617 PET/CT imaging of prostate adenocarcinoma: First in-human studies Cancer Biotherapy and Radiopharmaceuticals.</ref>
* [[Somatostatin receptor scintigraphy|Somatostatin receptor scintigraphy (SRS)]] and therapy of [[neuroendocrine]] diseases (NET) with [[radionuclides]] (PRRT)<ref>Mirzaei S, Bastati B, Lipp RW, Knoll P, Zojer N, Ludwig H. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors. Oncology. 2011;80(5-6):326-9. doi:10.1159/000329808. Epub 2011 Jul 25. PubMed PMID: 21791941.</ref><ref>Rosenberger I, Strauss A, Dobiasch S, Weis C, Szanyi S, Gil-Iceta L, Alonso E, González Esparza M, Gómez-Vallejo V, Szczupak B, Plaza-García S, Mirzaei S, Israel LL, Bianchessi S, Scanziani E, Lellouche JP, Knoll P, Werner J, Felix K, Grenacher L, Reese T, Kreuter J, Jiménez-González M. Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer. J Control Release. 2015 Sep 28;214:76-84.</ref><ref>Popov V, Gospavic R, Knoll P, Mirzaei S. Physiologically Based Pharmacokinetic (PBPK) model for biodistribution of radiolabeled peptides in patients with neuroendocrine tumours. Asia Oceania Journal of Nuclear Medicine & Biology.2016.</ref><ref>Ahmadihosseini H, Abedi J, Ghodsi Rad MA, Zakavi SR, Knoll P, Mirzaei S, Sadeghi R. Diagnostic utility of 99mTc-EDDA-tricine-HYNIC-Tyr3-octreotate SPECT for differentiation of active from inactive pulmonary tuberculosis. Nucl Med Commun. 2014 Dec;35(12):1262-7.</ref><ref>Mirzaei S, Sohlberg A, Knoll P, Zakavi R, Diemling M. Easy-to-use online software package for internal dose assessment after radionuclide treatment in clinical routine. Clin Nucl Med. 2013 Sep;38(9):686-90. doi:10.1097/RLU.0b013e31828da3db. PubMed PMID: 23640224.</Ref><ref>Neumann I, Mirzaei S, Birck R, Osinger K, Waldherr R, Köhn HD, Meisl FT. Expression of somatostatin receptors in inflammatory lesions and diagnostic value of somatostatin receptor scintigraphy in patients with ANCA-associated small vessel vasculitis. Rheumatology (Oxford). 2004 Feb;43(2):195-201.</ref>
* [[Somatostatin receptor scintigraphy|Somatostatin receptor scintigraphy (SRS)]] and therapy of [[neuroendocrine]] diseases (NET) with [[radionuclides]] (PRRT)<ref>Mirzaei S, Bastati B, Lipp RW, Knoll P, Zojer N, Ludwig H. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors. Oncology. 2011;80(5-6):326-9. {{doi|10.1159/000329808}}. Epub 2011 Jul 25. PubMed PMID 21791941.</ref><ref>Rosenberger I, Strauss A, Dobiasch S, Weis C, Szanyi S, Gil-Iceta L, Alonso E, González Esparza M, Gómez-Vallejo V, Szczupak B, Plaza-García S, Mirzaei S, Israel LL, Bianchessi S, Scanziani E, Lellouche JP, Knoll P, Werner J, Felix K, Grenacher L, Reese T, Kreuter J, Jiménez-González M. Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer. J Control Release. 2015 Sep 28;214:76-84.</ref><ref>Popov V, Gospavic R, Knoll P, Mirzaei S. Physiologically Based Pharmacokinetic (PBPK) model for biodistribution of radiolabeled peptides in patients with neuroendocrine tumours. Asia Oceania Journal of Nuclear Medicine & Biology.2016.</ref><ref>Ahmadihosseini H, Abedi J, Ghodsi Rad MA, Zakavi SR, Knoll P, Mirzaei S, Sadeghi R. Diagnostic utility of 99mTc-EDDA-tricine-HYNIC-Tyr3-octreotate SPECT for differentiation of active from inactive pulmonary tuberculosis. Nucl Med Commun. 2014 Dec;35(12):1262-7.</ref><ref>Mirzaei S, Sohlberg A, Knoll P, Zakavi R, Diemling M. Easy-to-use online software package for internal dose assessment after radionuclide treatment in clinical routine. Clin Nucl Med. 2013 Sep;38(9):686-90. {{doi|10.1097/RLU.0b013e31828da3db}}. PubMed PMID 23640224.</ref><ref>Neumann I, Mirzaei S, Birck R, Osinger K, Waldherr R, Köhn HD, Meisl FT. Expression of somatostatin receptors in inflammatory lesions and diagnostic value of somatostatin receptor scintigraphy in patients with ANCA-associated small vessel vasculitis. Rheumatology (Oxford). 2004 Feb;43(2):195-201.</ref>
* Benign and malign [[thyroid diseases]]<ref>Zandieh S, Bernt R, Zwerina J, Haller J, Knoll P, Seyeddain O, Mirzaei S. Acoustic Structure Quantification Analysis of the Thyroid in Patients with Diffuse Autoimmune Thyroid Disease. Ultrason Imaging. 2016 Mar;38(2):137-47. doi:10.1177/0161734615580766. Epub 2015 Apr 8. PubMed PMID: 25855160.</ref><ref>Zandieh S, Pokieser W, Knoll P, Sonneck-Koenne C, Kudlacek M, Mirzaei S. Oncocytic adenomas of thyroid-mimicking benign or metastatic disease on 18F-FDG-PET scan. Acta Radiol. 2015 Jun;56(6):709-13. doi:10.1177/0284185114537928. Epub 2014 Jun 19. PubMed PMID: 24948789.</Ref><ref>Schnedl WJ, Mirzaei S, Wallner-Liebmann SJ, Tafeit E, Mangge H, Krause R, Lipp RW. Improvement of Cerebral Hypoperfusion with Levothyroxine Therapy in Hashimoto's Encephalopathy Demonstrated by (99m)Tc-HMPAO-SPECT. Eur Thyroid J. 2013 Jun;2(2):116-9. doi: 10.1159/000348523. Epub 2013 Apr 12. PubMed PMID:24783049; PubMed Central PMCID: PMC3821506.</Ref><ref>Pestitschek M, Sonneck-Koenne C, Zakavi SR, Li S, Knoll P, Mirzaei S. Selenium intake and selenium blood levels: a novel food frequency questionnaire. Wien Klin Wochenschr. 2013 Mar;125(5-6):160-4. doi: 10.1007/s00508-013-0334-2. Epub 2013 Mar 19. PubMed PMID: 23508871.</ref><ref>Mirzaei S, Krotla G, Knoll P, Koriska K, Köhn H. Possible effect of calcitonin deficiency on bone mass after subtotal thyroidectomy. Acta Med Austriaca. 1999;26(1):29-31. PubMed PMID: 10230474.</ref>
* Benign and malign [[thyroid diseases]]<ref>Zandieh S, Bernt R, Zwerina J, Haller J, Knoll P, Seyeddain O, Mirzaei S. Acoustic Structure Quantification Analysis of the Thyroid in Patients with Diffuse Autoimmune Thyroid Disease. Ultrason Imaging. 2016 Mar;38(2):137-47. {{doi|10.1177/0161734615580766}}. Epub 2015 Apr 8. PubMed PMID 25855160.</ref><ref>Zandieh S, Pokieser W, Knoll P, Sonneck-Koenne C, Kudlacek M, Mirzaei S. Oncocytic adenomas of thyroid-mimicking benign or metastatic disease on 18F-FDG-PET scan. Acta Radiol. 2015 Jun;56(6):709-13. {{doi|10.1177/0284185114537928}}. Epub 2014 Jun 19. PubMed PMID 24948789.</Ref><ref>Schnedl WJ, Mirzaei S, Wallner-Liebmann SJ, Tafeit E, Mangge H, Krause R, Lipp RW. Improvement of Cerebral Hypoperfusion with Levothyroxine Therapy in Hashimoto's Encephalopathy Demonstrated by (99m)Tc-HMPAO-SPECT. Eur Thyroid J. 2013 Jun;2(2):116-9. {{doi|10.1159/000348523}}. Epub 2013 Apr 12. PubMed PMID 24783049; PubMed Central PMCID: PMC3821506.</Ref><ref>Pestitschek M, Sonneck-Koenne C, Zakavi SR, Li S, Knoll P, Mirzaei S. Selenium intake and selenium blood levels: a novel food frequency questionnaire. Wien Klin Wochenschr. 2013 Mar;125(5-6):160-4. {{doi|10.1007/s00508-013-0334-2}}. Epub 2013 Mar 19. PubMed PMID 23508871.</ref><ref>Mirzaei S, Krotla G, Knoll P, Koriska K, Köhn H. Possible effect of calcitonin deficiency on bone mass after subtotal thyroidectomy. Acta Med Austriaca. 1999;26(1):29-31. PubMed PMID 10230474.</ref>


== Honors and awards ==
== Honors and awards ==
Line 46: Line 46:


== Memberships in organisations ==
== Memberships in organisations ==
Mirzaei's research activity is connected with memberships in various organisations.<ref name=a>[http://www.vienna-omi.at/en/uploads/pdf/mentors/WIL_Mirzaei.pdf CV Mirzaei Siroos]</ref> He was more than ten years Head of the Education working group as well as Board Member of the ''Austrian Society of Nuclear Medicine'', President of the ''Austrian Nuclear Medicine Physician Union'' and member of the Executive Committee of the ''European Board of Nuclear Medicine (UEMS)''.<ref>[http://uems.eanm.org/index.php?id=10 European Association of Nuclear Medicine (EBDN), Executive Committee]</ref> Besides, he contributes his expertise to the ''Austrian Society for Radiation Protection'', the ''Society of Nuclear Medicine (SNM)'', USA and the organisation ''[[Doctors without Borders]]''. Furthermore, he is speaker of the medical division of [[Amnesty International]] Austria, expert in the field of torture diagnostics in the [[Istanbul Protocol]]<ref>[http://www.istanbulprotocol.info/index.php/en/find-an-expert Istanbul Protocol, list of experts]</ref> and founding member of the organisation ''HEMAYAT''.<ref>[http://www.hemayat.org/informationen/english.html HEMAYAT.org]</ref>
Mirzaei's research activity is connected with memberships in various organisations.<ref name="a"/> He was more than ten years Head of the Education working group as well as Board Member of the ''Austrian Society of Nuclear Medicine'', President of the ''Austrian Nuclear Medicine Physician Union'' and member of the Executive Committee of the ''European Board of Nuclear Medicine (UEMS)''.<ref>[http://uems.eanm.org/index.php?id=10 European Association of Nuclear Medicine (EBDN), Executive Committee]</ref> Besides, he contributes his expertise to the ''Austrian Society for Radiation Protection'', the ''Society of Nuclear Medicine (SNM)'', USA and the organisation ''[[Doctors without Borders]]''. Furthermore, he is speaker of the medical division of [[Amnesty International]] Austria, expert in the field of torture diagnostics in the [[Istanbul Protocol]]<ref>[http://www.istanbulprotocol.info/index.php/en/find-an-expert Istanbul Protocol, list of experts]</ref> and founding member of the organisation ''HEMAYAT''.<ref>[http://www.hemayat.org/informationen/english.html HEMAYAT.org]</ref>


Mirzaei is also member of the Editorial Board of the following scientific journals: ''Asia Oceania Journal of Nuclear Medicine & Biology'',<ref>[http://aojnmb.mums.ac.ir/journal/editorial.board Asia Oceania Journal of Nuclear Medicine & Biology, Editorial Board Members]</ref> ''Iranian Journal of Nuclear Medicine''<ref>[http://irjnm.tums.ac.ir/journal/editorial.board Iranian Journal of Nuclear Medicine, Editorial Board Members]</ref> and ''BMC International Health & Human Rights''.
Mirzaei is also member of the Editorial Board of the following scientific journals: ''Asia Oceania Journal of Nuclear Medicine & Biology'',<ref>[http://aojnmb.mums.ac.ir/journal/editorial.board Asia Oceania Journal of Nuclear Medicine & Biology, Editorial Board Members]</ref> ''Iranian Journal of Nuclear Medicine''<ref>[http://irjnm.tums.ac.ir/journal/editorial.board Iranian Journal of Nuclear Medicine, Editorial Board Members]</ref> and ''BMC International Health & Human Rights''.
Line 68: Line 68:
* [http://derstandard.at/1277337195789/daStandardat-Interview-Das-Leid-anerkennen "Das Leid anerkennen", Interview with Siroos Mirzaei, [[Der Standard]] (in German)]
* [http://derstandard.at/1277337195789/daStandardat-Interview-Das-Leid-anerkennen "Das Leid anerkennen", Interview with Siroos Mirzaei, [[Der Standard]] (in German)]


⚫
{{DEFAULTSORT:Mirzaei, Siroos}}
<!--- Categories --->
<!--- Categories --->
⚫
{{DEFAULTSORT: Mirzaei, Siroos}}
[[Category:1963 births]]
[[Category:1963 births]]
[[Category:Living people]]
[[Category:Living people]]

Revision as of 05:07, 22 August 2016

Siroos Mirzaei
Born (1963-04-22) April 22, 1963 (age 61)
Mashhad
Scientific career
FieldsTorture diagnostics, Dementia diagnostics, thyroid diseases, neuroendocrine diseases (NET)
InstitutionsWilhelminen Hospital in Vienna

Siroos Mirzaei (born 22 April 1963 in Mashhad) is an Iranian general practitioner and specialist in Nuclear Medicine. He is Head of the Department of Nuclear Medicine of the Wilhelminen Hospital in Vienna.[1] Mirzaei is well-known for his scientific work on torture diagnostics with molecular imaging methods.

Biography

Mirzaei spent his childhood and adolescence in Mashhad, Iran. When he was 18 years old, he moved to Austria to study medicine at the University of Vienna.[2] He graduated in 1987 and after some experimental jobs i.e. at the Department of Experimental Anesthesiology of the Vienna General Hospital he moved in 1989 to Luxemburg to continue his postdoctoral education at the Department of Cardiology and the Department of Infectious Diseases of the Centre Hospitalier de Luxembourg. In 1994 he completed his specialist training in Family Medicine at the Kaiserin Elisabeth Hospital in Vienna and received the Board Certification in General Medicine. In 1994, he changed to Wilhelminen Hospital in Vienna to complete his specialist medical training in Nuclear Medicine which he was certified for in 1998. In the same year, Mirzaei went to Heidelberg, Germany for a research sabbatical at the Department of Endocrinology of the Ruprecht-Karls-University and afterwards he started to work as Staff Physician at the Wilhelminen Hospital Vienna. In 2004, Mirzaei was appointed professor for Nuclear Medicine at the University of Vienna. Since 2007, he has been Head of the Department of Nuclear Medicine at the Wilhelminen Hospital Vienna.[1]

Scientific contribution

Mirzaei has been contributing to the following fields of research:

Honors and awards

  • 1996: Elscint Programmier Förderungspreis for the project “Iterative reconstruction of SPECT-Data on an Elscint-Workstation“
  • 1999: Mallinckrodt Förderungspreis Nuklearmedizin for the study "Bone Scintigraphy in Screening of Torture Survivors“ published in The Lancet[34]
  • 2000: Solidarity Prize of the archdiocese Vienna for the influence of the his work on Integration (Hemayat)
  • In 2008, Mirzaei himself has introduced a price called "Young Human Rights Activist Award 2008", which was won by a team from India for its innovative concept on human rights.[35]

Memberships in organisations

Mirzaei's research activity is connected with memberships in various organisations.[2] He was more than ten years Head of the Education working group as well as Board Member of the Austrian Society of Nuclear Medicine, President of the Austrian Nuclear Medicine Physician Union and member of the Executive Committee of the European Board of Nuclear Medicine (UEMS).[36] Besides, he contributes his expertise to the Austrian Society for Radiation Protection, the Society of Nuclear Medicine (SNM), USA and the organisation Doctors without Borders. Furthermore, he is speaker of the medical division of Amnesty International Austria, expert in the field of torture diagnostics in the Istanbul Protocol[37] and founding member of the organisation HEMAYAT.[38]

Mirzaei is also member of the Editorial Board of the following scientific journals: Asia Oceania Journal of Nuclear Medicine & Biology,[39] Iranian Journal of Nuclear Medicine[40] and BMC International Health & Human Rights.

Publications

Mirzaei has published over 100 articles in scientific journals.

He is also author of the following two books:

  • Mirzaei, Siroos; Irdische Träume im Paradies: Roman. Innsbruck: Tiroler Autorinnen u. Autoren Koop., 2012. ISBN 978-3-900888-53-4
  • Mirzaei, Siroos; Schenk, Martin: Images of Torture. Heyamat: 15 Years of Work with Traumatised Refugees. Wien: Mandelbaum Verlag, 2010. ISBN 978385476-351-2[41]

See also: List of Publications on Mirzaei's Homepage

References

  1. ^ a b Department of Nuclear Medicine, Wilhelminen Vienna
  2. ^ a b CV Mirzaei Siroos
  3. ^ Zandieh S, Bernt R, Knoll P, Wenzel T, Hittmair K, Haller J, Hergan K, Mirzaei S. Analysis of the Metabolic and Structural Brain Changes in Patients With Torture-Related Post-Traumatic Stress Disorder (TR-PTSD) Using 18F-FDG PET and MRI. Medicine (Baltimore). 2016 Apr;95(15):e3387. doi:10.1097/MD.0000000000003387. PubMed PMID 27082610; PubMed Central PMCID:PMC4839854.
  4. ^ Wenzel T, Frewer A, Mirzaei S. The DSM 5 and the Istanbul Protocol: Diagnosis of psychological sequels of torture. Torture. 2015;25(1):51-61. Review. PubMed PMID 26021347.
  5. ^ Mirzaei S, Sonneck-Koenne C, Bruecke T, Aryana K, Knoll P, Zakavi R. Supplementary value of functional imaging in forensic medicine. Torture. 2012;22 Suppl 1:14-20. PubMed PMID 22948398.
  6. ^ Mirzaei S, Knoll P, Köhn H. [Medical aspects of objectifying torture sequels]. Wien Klin Wochenschr. 2004 Aug 31;116(15-16):568-74. German. PubMed PMID 15471186.
  7. ^ Mirzaei S, Knoll P, Keck A, Preitler B, Gutierrez E, Umek H, Köhn H, Pecherstorfer M. Regional cerebral blood flow in patients suffering from post-traumatic stress disorder. Neuropsychobiology. 2001;43(4):260-4. PubMed PMID 11340366.
  8. ^ Wenzel T, Griengl H, Stompe T, Mirzaei S, Kieffer W. Psychological disorders in survivors of torture: exhaustion, impairment and depression. Psychopathology. 2000 Nov-Dec;33(6):292-6. PubMed PMID 11060511.
  9. ^ Mirzaei S, Knoll P, Lipp RW, Wenzel T, Koriska K, Köhn H. Bone scintigraphy in screening of torture survivors. Lancet. 1998 Sep 19;352(9132):949-51. PubMed PMID 9752817.
  10. ^ Capasso E, Durzu S, Piras S, Zandieh S, Knoll P, Haug A, Hacker M, Meleddu C, Mirzaei S. Role of (64)CuCl 2 PET/CT in staging of prostate cancer. Ann Nucl Med. 2015 Jul;29(6):482-8. doi:10.1007/s12149-015-0968-4. Epub 2015 Apr 2. PubMed PMID 25833290.
  11. ^ Zandieh S, Pokieser W, Knoll P, Sonneck-Koenne C, Kudlacek M, Mirzaei S. Oncocytic adenomas of thyroid-mimicking benign or metastatic disease on 18F-FDG-PET scan. Acta Radiol. 2015 Jun;56(6):709-13. doi:10.1177/0284185114537928. Epub 2014 Jun 19. PubMed PMID 24948789.
  12. ^ Ahmadzadehfar H, Rodrigues M, Zakavi R, Knoll P, Mirzaei S. Prognostic significance of the standardized uptake value of pre-therapeutic (18)F-FDG PET in patients with malignant lymphoma. Med Oncol. 2011 Dec;28(4):1570-6. doi:10.1007/s12032-010-9584-2. Epub 2010 Jun 4. PubMed PMID 20524086.
  13. ^ Prosch H, Mirzaei S, Oschatz E, Strasser G, Huber M, Mostbeck G. Case report: Gluteal injection site granulomas: false positive finding on FDG-PET in patients with non-small cell lung cancer. Br J Radiol. 2005 Aug;78(932):758-61. PubMed PMID 16046432.
  14. ^ Fink AM, Holle-Robatsch S, Herzog N, Mirzaei S, Rappersberger K, Lilgenau N, Jurecka W, Steiner A. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res. 2004 Apr;14(2):141-5. PubMed PMID 15057045.
  15. ^ Mirzaei S, Guerchaft M, Bonnier C, Knoll P, Doat M, Braeutigam P. Use of segmented CT transmission map to avoid metal artifacts in PET images by a PET-CT device. BMC Nucl Med. 2005 Jun 14;5(1):3. PubMed PMID 15953395; PubMed Central PMCID: PMC1164418.
  16. ^ Mirzaei S, Schratter-Sehn AU, Knoll P, Gerber E, Kumpan W, Schiessel R, Raderer M, Köhn H. [Determination of therapy management in rectal carcinoma by staging with 18-FDG-PET]. Chirurg. 2001 Sep;72(9):1058-61. German. PubMed PMID 11594277.
  17. ^ Mirzaei S, Knoll P, Kohn H. Diagnosis of recurrent astrocytoma with fludeoxyglucose F18 PET scanning. N Engl J Med. 2001 Jun 28;344(26):2030-1. PubMed PMID 11430342.
  18. ^ Dimou E, Booij J, Rodrigues M, Prosch H, Attems J, Knoll P, Zajicek B, Dudczak R, Mostbeck G, Kuntner C, Langer O, Bruecke T, Mirzaei S. Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment. Curr Alzheimer Res. 2009 Jun;6(3):312-9. Review. PubMed PMID 19519314.
  19. ^ Mirzaei S, Gelpi E, Booij J, Rodrigues M, Neumann I, Zaknun J, Koehn H, Knoll P. New approaches in nuclear medicine for early diagnosis of Alzheimer's disease. Curr Alzheimer Res. 2004 Aug;1(3):219-29. Review. PubMed PMID 15975069.
  20. ^ Mirzaei S, Rodrigues M, Koehn H, Knoll P, Bruecke T. Metabolic impairment of brain metabolism in patients with Lewy body dementia. Eur J Neurol. 2003 Sep;10(5):573-5. PubMed PMID 12940841.
  21. ^ Mirzaei S, Knoll P, Koehn H, Bruecke T. Assessment of diffuse Lewy body disease by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET). BMC Nucl Med. 2003 Feb 20;3(1):1. PubMed PMID 12625839; PubMed Central PMCID: PMC151666.
  22. ^ B Grubmüller, R P Baum, E Capasso, A Singh, Y Ahmadi, P Knoll, A Floth, S Righi, S Zandieh, C Meleddu, S F Shariat, H C Klingler, S Mirzaei (2016) 64Cu-PSMA-617 PET/CT imaging of prostate adenocarcinoma: First in-human studies Cancer Biotherapy and Radiopharmaceuticals.
  23. ^ Mirzaei S, Bastati B, Lipp RW, Knoll P, Zojer N, Ludwig H. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors. Oncology. 2011;80(5-6):326-9. doi:10.1159/000329808. Epub 2011 Jul 25. PubMed PMID 21791941.
  24. ^ Rosenberger I, Strauss A, Dobiasch S, Weis C, Szanyi S, Gil-Iceta L, Alonso E, González Esparza M, Gómez-Vallejo V, Szczupak B, Plaza-García S, Mirzaei S, Israel LL, Bianchessi S, Scanziani E, Lellouche JP, Knoll P, Werner J, Felix K, Grenacher L, Reese T, Kreuter J, Jiménez-González M. Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer. J Control Release. 2015 Sep 28;214:76-84.
  25. ^ Popov V, Gospavic R, Knoll P, Mirzaei S. Physiologically Based Pharmacokinetic (PBPK) model for biodistribution of radiolabeled peptides in patients with neuroendocrine tumours. Asia Oceania Journal of Nuclear Medicine & Biology.2016.
  26. ^ Ahmadihosseini H, Abedi J, Ghodsi Rad MA, Zakavi SR, Knoll P, Mirzaei S, Sadeghi R. Diagnostic utility of 99mTc-EDDA-tricine-HYNIC-Tyr3-octreotate SPECT for differentiation of active from inactive pulmonary tuberculosis. Nucl Med Commun. 2014 Dec;35(12):1262-7.
  27. ^ Mirzaei S, Sohlberg A, Knoll P, Zakavi R, Diemling M. Easy-to-use online software package for internal dose assessment after radionuclide treatment in clinical routine. Clin Nucl Med. 2013 Sep;38(9):686-90. doi:10.1097/RLU.0b013e31828da3db. PubMed PMID 23640224.
  28. ^ Neumann I, Mirzaei S, Birck R, Osinger K, Waldherr R, Köhn HD, Meisl FT. Expression of somatostatin receptors in inflammatory lesions and diagnostic value of somatostatin receptor scintigraphy in patients with ANCA-associated small vessel vasculitis. Rheumatology (Oxford). 2004 Feb;43(2):195-201.
  29. ^ Zandieh S, Bernt R, Zwerina J, Haller J, Knoll P, Seyeddain O, Mirzaei S. Acoustic Structure Quantification Analysis of the Thyroid in Patients with Diffuse Autoimmune Thyroid Disease. Ultrason Imaging. 2016 Mar;38(2):137-47. doi:10.1177/0161734615580766. Epub 2015 Apr 8. PubMed PMID 25855160.
  30. ^ Zandieh S, Pokieser W, Knoll P, Sonneck-Koenne C, Kudlacek M, Mirzaei S. Oncocytic adenomas of thyroid-mimicking benign or metastatic disease on 18F-FDG-PET scan. Acta Radiol. 2015 Jun;56(6):709-13. doi:10.1177/0284185114537928. Epub 2014 Jun 19. PubMed PMID 24948789.
  31. ^ Schnedl WJ, Mirzaei S, Wallner-Liebmann SJ, Tafeit E, Mangge H, Krause R, Lipp RW. Improvement of Cerebral Hypoperfusion with Levothyroxine Therapy in Hashimoto's Encephalopathy Demonstrated by (99m)Tc-HMPAO-SPECT. Eur Thyroid J. 2013 Jun;2(2):116-9. doi:10.1159/000348523. Epub 2013 Apr 12. PubMed PMID 24783049; PubMed Central PMCID: PMC3821506.
  32. ^ Pestitschek M, Sonneck-Koenne C, Zakavi SR, Li S, Knoll P, Mirzaei S. Selenium intake and selenium blood levels: a novel food frequency questionnaire. Wien Klin Wochenschr. 2013 Mar;125(5-6):160-4. doi:10.1007/s00508-013-0334-2. Epub 2013 Mar 19. PubMed PMID 23508871.
  33. ^ Mirzaei S, Krotla G, Knoll P, Koriska K, Köhn H. Possible effect of calcitonin deficiency on bone mass after subtotal thyroidectomy. Acta Med Austriaca. 1999;26(1):29-31. PubMed PMID 10230474.
  34. ^ Mirzaei, S, P Knoll, Rw Lipp, Th Wenzel, K Koriska, and H Köhn. “Bone Scintigraphy in Screening of Torture Survivors.” The Lancet 352, no. 9132 (September 1998): 949–51. doi:10.1016/S0140-6736(98)05049-1.
  35. ^ Young Human Rights Activist Award 2008, nominations and winner
  36. ^ European Association of Nuclear Medicine (EBDN), Executive Committee
  37. ^ Istanbul Protocol, list of experts
  38. ^ HEMAYAT.org
  39. ^ Asia Oceania Journal of Nuclear Medicine & Biology, Editorial Board Members
  40. ^ Iranian Journal of Nuclear Medicine, Editorial Board Members
  41. ^ Images of Torture, Mandelbaum publisher

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Siroos_Mirzaei&oldid=735650491"